First human test for potential psoriasis drug copy
NCT ID NCT07479576
Summary
This early-stage study aims to see how a new drug candidate, QL2106, compares to an existing psoriasis drug called Tremfye in healthy volunteers. Researchers will give a single dose to 190 healthy adults and closely track how the body processes each drug, its safety, and how the immune system reacts. The main goal is to gather initial data on whether QL2106 behaves similarly to the approved medication.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing GoBroad Hospital
Beijing, Beijing Municipality, 100000, China
Conditions
Explore the condition pages connected to this study.